Primary localised amyloidosis of the orbit


Abstract
Aim/background—Primary localised amyloidosis is rarely encountered in the orbit. The typical clinical and radiological appearances have not been clearly established, in particular the single site deposition of amyloid has never been proved.
Methods—Six cases were reviewed in detail and their clinical and radiological characteristics are described here. Four patients had scintigraphy with $^{123}$I serum amyloid P component and one patient had typing of the amyloid fibrils.
Results—All the patients had a firm mass in the upper orbit with a predilection for the region of the lacrimal gland. Computed tomography showed a homogeneous mass with thickening and irregularity of the adjacent bone and/or calcification within the mass. None was associated with systemic disease. Scintigraphy with $^{123}$I serum amyloid P component demonstrated that the amyloid was confined to the orbit. In one patient the amyloid fibrils were derived from an IgG4 heavy chain constant domain. The lesions were partially excised with subsequent clinical stability over 6 months to 18 years in all but one patient who had continued enlargement of the lesion.
Conclusion—There is a characteristic clinical and radiological pattern for primary localised amyloidosis of the orbit. The disease process is truly local and not part of a systemic process. A majority respond to simple debulking with subsequent observation.

Amyloidosis is a disorder of protein metabolism characterised by the extracellular deposition of abnormal protein fibrils. It may be localised or distributed throughout the body, causing organ damage and serious morbidity. Major visceral involvement, especially of the kidneys and heart, is usually fatal. The fibrils which form the bulk of amyloid deposits are derived from a variety of precursor proteins in different forms of the disease but are always intimately associated with sulphated glycosaminoglycans. In addition, the normal circulating glycoprotein, serum amyloid P component (SAP), specifically binds to the fibrils and is a universal constituent of amyloid deposits.

Amyloid in the orbit is rare; there are only 27 previously reported cases. It usually occurs in isolation, not as part of a systemic disease. Previous reports have usually been limited to single case histories and the overall clinical pattern of presentation and radiology has not been well documented. Localisation of amyloid just to the orbit has usually not been established and apart from one of the cases in the present study the fibril protein has been identified only once before.

Methods
Six cases of primary localised amyloidosis were reviewed in detail.

CASE 1
A 60-year-old man noticed a slowly progressive drooping of the right upper lid for 12 years and double vision when looking down for 4 months. He was fit and healthy with no previous illness. There was a right ptosis of 2 mm. The right eye was proposed 4 mm and displaced downwards 10 mm. There was no other significant ocular abnormality.

Plain films of the orbits were normal. Computed tomography (CT) revealed a $2 \times 2$ cm soft tissue mass, slightly denser than the brain, in the upper portion of the right orbit. The lesion was rounded, but more irregular superiorly, moulded to the globe, which it displaced anteroinferiorly, and extended forwards into the upper lid. There was questionable irregularity of the adjacent bone of the roof of the orbit, with possibly a small spicule of calcific density related to it. The paranasal sinuses showed evidence of widespread inflammatory disease.

The lesion was approached trans-septally and the major portion of the mass excised. Histology showed a hypocellular mass of fibrous tissue and amyloid. The amyloid had a predominantly perivascular location. A small number of lymphoid cells were also present. Scintigraphy with $^{123}$I SAP was performed. There has been no recurrence during a follow up of 6 years.

CASE 2
An 87-year-old man with mild bronchitis and an 8 year history of non-insulin dependent diabetes mellitus noticed a painless progressive swelling of his left upper lid for 6 months. The left eye was displaced medially 3 mm by a firm subcutaneous mass in the upper lid which extended subconjunctivally over the lateral part of the globe. The palpebral aperture was narrowed by 6 mm and there was restriction of vertical and horizontal movement of the globe. Ocular examination was otherwise normal.

CT showed a $2 \times 1$ cm homogeneous soft tissue mass in the region of the left lacrimal gland, whose density was slightly higher than that of the brain. The mass appeared to involve the anterior end of the lateral rectus muscle. There was generalised sinusitis.
experienced periorcular discomfort once or twice a week, aggravated by vomiting or straining. There was a firm fixed mass of 2 cm by 1 cm attached to bone at the right lateral canthus with a palpable irregularity of the adjacent bone. The right eye was proptosed 1 mm and displaced 4 mm medially. There was no other ocular abnormality.

CT showed a mass in the right lacrimal fossa, 1 cm in transverse and 2 cm in anteroposterior diameter. The lower part of the lesion was of soft tissue density, slightly denser than the brain, but its upper part was densely calcified, resembling a lobulated nodule of bone (Fig 2), with a less dense centre. The anterior portion of the lateral rectus muscle may have been involved by the mass, which was moulded to the globe, displacing it downwards and forwards. An apparent plane of cleavage was visible between the calcified or ossified component and the lateral wall of the orbit, but the latter was thickened and there was also a small fleck of calcification near its outer surface, in the temporal fossa. CT 15 months later showed some progression of the mass, particularly the calcified or ossified portion.

Two orbital biopsies were taken 12 months apart. The amyloid tissue was exposed and further dissection showed that the superotemporal orbital wall was soft and red. Biopsies taken from this area and from the amorphous material in the lacrimal fossa contained abundant amyloid (Fig 3). The bone around the amyloid was decalcified and showed formation of woven bone and remodelling of lamellar bone with osteoclastic activity. There was variable recalcification. Scintigraphy with $^{123}$I SAP was performed. The lesion has remained static over a further 4 years of follow up.

CASE 4
A 42-year-old woman had noticed a swelling in the inner aspect of her left upper lid for 18 months. There were no past illnesses. The left eye was displaced 4 mm laterally and 2 mm inferiorly by a firm mass deep to the medial upper lid, measuring 4 x 1 cm. This mass could be seen in the upper fornix as an area of grey tissue beneath the conjunctiva. There was no other ocular or orbital abnormality.

CT demonstrated a somewhat inhomogeneous soft tissue mass, slightly denser than the brain, in the superior temporal quadrant of the right orbit. It measured 2.5 cm in anteroposterior diameter, 2 cm across, and was 1 cm thick. The mass was rounded, moulded to the globe (Fig 4), and appeared to involve the superior rectus muscle. The overlying bone was thickened with a focal zone of irregular calcification or ossification posteriorly either on the undersurface of the bone or separate from it. There was generalised sinusitis.

The lesion was biopsied and showed extensive amorphous material staining positively for amyloid with occasional blood vessels and some mild chronic inflammatory cell infiltration. Scintigraphy with $^{123}$I SAP was performed. Over 3 years of follow up the mass has slowly enlarged. As vision is not threatened it has been decided that the risks of surgical

CASE 3
A 29-year-old woman with no history of previous illness had a 4 year history of recurrent periorbital bruising and a lump in the lateral part of her right upper eyelid (Fig 1). She

Biopsy of the mass revealed dense interstitial and vascular wall amyloid, with small chronic inflammatory cell aggregates. Follow up is limited to the immediate postoperative period.
Primary localised amyloidosis of the orbit

Figure 4  Primary localised amyloidosis of the orbit, non-homogeneous orbital tissue mass lateral to and above right eye, case 4.

intervention outweigh the benefits, so a conservative approach has been adopted.

CASE 5
A 67-year-old man noticed drooping and swelling of his left upper lid for 7 months. There was a firm subcutaneous, mobile mass superotemporally in his left orbit with no proptosis or displacement of the globe. His left palpebral aperture was narrowed by 2 mm. No other ocular or orbital abnormality was found.

CT showed generalised but predominantly anterior, smooth expansion of the left lacrimal gland, which was of slightly higher density than the brain. The gland was moulded to the globe, which was displaced downwards and forwards. The adjacent bone appeared normal.

The lesion was biopsied and found to be within the lacrimal gland. Histology showed amyloid interspersed with blood vessels and mild chronic inflammatory cell infiltration. Over the subsequent 6 months there has been no progression of the lesion.

CASE 6
A 75-year-old woman, blind in her left eye from childhood trauma, noticed drooping of her right upper eyelid for approximately 1 year. She had no history of any systemic illness. Her acuity was 6/9 and colour vision was normal. There was right periorbital oedema with 6 mm proptosis, 6 mm medial and 3 mm inferior deviation of the globe. The right eye could not abduct and all other movements were severely restricted.

CT showed a mass, generally smooth and lobulated, in the superior temporal quadrant of the right orbit. It was 3 cm in anteroposterior diameter, 2.5 cm across, and 2 cm vertically. The mass could not be separated radiologically from the lateral rectus muscle, and the superior rectus was also swollen. It was moulded to the globe, which it displaced downwards and forwards. The overlying bone was thinned. A small focus of calcification, resembling a phlebolith, was seen within the lateral part of the mass, adjacent to but separate from the bone of the lateral wall of the orbit.

Biopsy showed amyloid within the lacrimal gland, particularly around vessels, and a chronic inflammatory cell infiltrate. Whole body scintigraphy with $^{123}$I SAP was performed. Amyloid fibrils were isolated from resected tissue and the subunit protein was characterised by amino acid sequencing. There has been no progression of the lesion over 2 years of subsequent review.

Results
The most common presenting symptoms of primary localised orbital amyloid are ptosis, proptosis, and global displacement with no visual impairment. The lesion is typically a firm, non-tender, easily palpable mass in the superotemporal aspect of the orbit. In five cases the lacrimal gland was intimately involved with the amyloid mass.

CT scanning is the most helpful method of imaging. It typically shows a soft tissue mass in the superotemporal quadrant of the orbit, often centimetres in diameter and extending forwards to involve the upper lid. It is usually rather homogeneous, slightly denser than brain, and may show homogeneous contrast enhancement. Associated thickening and irregularity of adjacent bone and/or calcification within the soft tissue mass are changes suggestive of the diagnosis.

In no case was the biopsy proved orbital amyloid found to be part of a systemic disease. Scintigraphy in cases 1, 3, 4, and 6 proved the lesion to be unique to the orbit. Amino acid sequencing of the protein chain in the amyloid fibrils of case 6 showed it to be a constant domain of the heavy chain of IgG4.

Discussion
Amyloid P component (AP) is a universal constituent of amyloid deposits and is derived from the normal circulating plasma protein, serum amyloid P component. Isolated pure human SAP radiolabelled with $^{123}$I has been developed as a highly specific, sensitive, quantitative diagnostic tracer for all types of amyloidosis. It was used in four of our patients to demonstrate that the amyloid was confined to the orbit. Although SAP scintigraphy cannot exclude microscopic amyloid deposits elsewhere the negative results were in accord with the absence of any demonstrable visceral or other organ dysfunction.

Conlon et al in 1991 reported that the amyloid deposits in a 72-year-old woman who presented with bilateral lacrimal gland swelling showed immunohistochemical and immunoelectron microscopic staining for immunoglobulin A light chains. Case 6 in this series is the first case of localised orbital amyloidosis in which amyloid fibrils have been extracted, allowing direct chemical identification of the fibril protein in this individual as the third constant domain of $\gamma$ heavy chains of IgG4 subclass. While amyloid derived from Ig heavy chains is extremely rare, this being only the third reported example, monoclonal Ig light chains are very commonly the cause of both systemic and localised forms of amyloidosis. In all such cases there is an underlying clonal
disorder of cells of B lymphocyte lineage, leading to monoclonal gammopathy that may be overt, as in multiple myeloma or so-called benign monoclonal gammopathy, or occult, presenting only with amyloid. All forms of extracerebral solitary amyloid mass lesions that have been biochemically characterised have been of this Ig light chain, so called AL type.

In five of our cases the lacrimal gland was intimately involved with the amyloid mass. There are no lymphatic vessels within the orbit with the exception of the lacrimal gland. The predilection for the lacrimal gland in the majority of patients with orbital amyloid may be due to the presence of these lymphatics and is compatible with a clonal B lymphocyte basis for this condition. All of our cases remained unilateral in contrast with systemic amyloidosis in which the lacrimal gland is frequently involved bilaterally.

Twenty seven cases of orbital amyloid have been reported previously. Three of these were possibly secondary to infection or systemic disease. The remaining 24 cases show a very similar pattern of presentation to our present series. The reported cases also find the three most common presenting symptoms to be proptosis, ptosis, and global displacement, with visual impairment due to the lesion being recorded only three times. The amyloid deposit is characteristically unilateral (19 reported cases) and confined to the upper part of the orbit (18 reported cases). Most (15) were described as hard or firm, fairly easily palpable and not tender. In one of our cases and in five of the reported cases of orbital mass, the mass was noted to be fixed to bone. Two further reports record a fixed mass.

Comprehensive radiological reports of primary amyloid masses in the orbits are rare. Moseley and Sanders reported a patient with a large mass in the upper part of the right orbit which was radiologically inseparable from the lateral and superior rectus muscles. There was no other abnormality on the films and the mass increased in size over an 8 month period of radiological observation. In four of our cases there was involvement of the rectus muscles, an observation made three times before.

These radiological findings are non-specific but in four of our cases and a further four reported cases associated thickening and irregularity of the adjacent bone and/or zones of calcification or ossification within the soft tissue mass were apparent. These changes are much more suggestive of the diagnosis.

Only one case report exists of magnetic resonance imaging in this condition. A proton density axial section showed a lesion of non-specific soft tissue intensity in an unusual position, below and abutting the optic nerve, which the authors mistook for a meningioma. Since calcification is helpful in differentiating amyloid from other lesions MRI is less suited than CT for imaging orbital amyloid.

The management of orbital amyloidosis is difficult. Most lesions slowly enlarge and cause problems by displacing the globe. Total excision is usually impossible and surgery should be directed to the excision of the major portion of the mass with the preservation of the palpebral lobe of the lacrimal gland, thelevator palpebrae superioris, and the rectus muscles.

We thank many other ophthalmologists involved in the management of these patients for their help. Characterisation of the amyloid fibril protein and studies of 123I SAP were supported by MRC Programme Grant G7900510 to MRG Rose, consultant ophthalmologist, kindly donated the photograph used for Figure 1.
